Valentina Forni Ogna1, Isabelle Menetrey1, Olivier Muller2, Eric Tousset3, Linda Guihard1, Pierre Fontana4, Eric Eeckhout2, Chin B Eap5, Bernard Vrijens3, Michel Burnier1, Grégoire Wuerzner1. 1. Service of Nephrology and Hypertension, Department of Medicine, Lausanne University Hospital, Lausanne, Switzerland. 2. Department of Cardiology, Lausanne University Hospital, Lausanne, Switzerland. 3. Aardex Group, Visé, Belgium. 4. Division of Angiology and Hemostasis, Geneva University Hospital and Faculty of Medicine, Geneva, Switzerland. 5. Unit of Biochemistry and Clinical Psychopharmacology, Center for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital, Lausanne, Switzerland.
Abstract
AIMS: The biological response to clopidogrel is highly variable and a poor responsiveness is associated with major adverse cardiac events. Adherence to therapy is a major cause of poor responsiveness but its impact on long-term platelet inhibition is unknown. The objective of the present study was to evaluate the effect of different programmes monitoring adherence to clopidogrel on platelet reactivity. METHODS: The study took the form of a monocentric, parallel group, randomized controlled trial. Adults treated with clopidogrel75 mg after elective coronary stenting were randomized into one of three groups: (i) a standard of care group; (ii) a standard of care + adherence electronic monitoring group, in which drug intake was recorded but kept blinded until the study end; or (iii) an integrated care group, with regular feedback on recorded adherence. Clopidogrel response was assessed with the vasodilator-stimulated phosphoprotein-platelet reactivity index (VASP-PRI) at randomization, 3 months and 6 months. RESULTS:A total of 123 adults were enrolled and randomized. Baseline VASP-PRI was highly variable, with a mean of 48 ± 18.8%. No difference between groups in VASP-PRI was found at 6 months (P = 0.761), despite better adherence to clopidogrel in the integrated care group. However, adherence (P = 0.035) and baseline VASP-PRI (P = 0.015) were associated with VASP-PRI at 3 months and 6 months. The association between adherence and VASP-PRI was lost in patients with baseline VASP-PRI > 50%. Diabetes, CYP2C19*2 carrier status and body mass index were significant predictors of VASP-PRI. CONCLUSIONS: The platelet response to clopidogrel during chronic therapy remained highly variable, despite high adherence. Different adherence monitoring programmes did not affect VASP-PRI at 6 months. Poor adherence is associated with lower VASP-PRI only in initial good responders to clopidogrel.
RCT Entities:
AIMS: The biological response to clopidogrel is highly variable and a poor responsiveness is associated with major adverse cardiac events. Adherence to therapy is a major cause of poor responsiveness but its impact on long-term platelet inhibition is unknown. The objective of the present study was to evaluate the effect of different programmes monitoring adherence to clopidogrel on platelet reactivity. METHODS: The study took the form of a monocentric, parallel group, randomized controlled trial. Adults treated with clopidogrel 75 mg after elective coronary stenting were randomized into one of three groups: (i) a standard of care group; (ii) a standard of care + adherence electronic monitoring group, in which drug intake was recorded but kept blinded until the study end; or (iii) an integrated care group, with regular feedback on recorded adherence. Clopidogrel response was assessed with the vasodilator-stimulated phosphoprotein-platelet reactivity index (VASP-PRI) at randomization, 3 months and 6 months. RESULTS: A total of 123 adults were enrolled and randomized. Baseline VASP-PRI was highly variable, with a mean of 48 ± 18.8%. No difference between groups in VASP-PRI was found at 6 months (P = 0.761), despite better adherence to clopidogrel in the integrated care group. However, adherence (P = 0.035) and baseline VASP-PRI (P = 0.015) were associated with VASP-PRI at 3 months and 6 months. The association between adherence and VASP-PRI was lost in patients with baseline VASP-PRI > 50%. Diabetes, CYP2C19*2 carrier status and body mass index were significant predictors of VASP-PRI. CONCLUSIONS: The platelet response to clopidogrel during chronic therapy remained highly variable, despite high adherence. Different adherence monitoring programmes did not affect VASP-PRI at 6 months. Poor adherence is associated with lower VASP-PRI only in initial good responders to clopidogrel.
Authors: Roxana Mehran; Sunil V Rao; Deepak L Bhatt; C Michael Gibson; Adriano Caixeta; John Eikelboom; Sanjay Kaul; Stephen D Wiviott; Venu Menon; Eugenia Nikolsky; Victor Serebruany; Marco Valgimigli; Pascal Vranckx; David Taggart; Joseph F Sabik; Donald E Cutlip; Mitchell W Krucoff; E Magnus Ohman; Philippe Gabriel Steg; Harvey White Journal: Circulation Date: 2011-06-14 Impact factor: 29.690
Authors: Stephen Ph Alexander; Doriano Fabbro; Eamonn Kelly; Neil Marrion; John A Peters; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Christopher Southan; Jamie A Davies Journal: Br J Pharmacol Date: 2015-12 Impact factor: 8.739
Authors: Willibald Hochholzer; Dietmar Trenk; Martin F Fromm; Christian M Valina; Christian Stratz; Hans-Peter Bestehorn; Heinz Joachim Büttner; Franz-Josef Neumann Journal: J Am Coll Cardiol Date: 2010-06-01 Impact factor: 24.094
Authors: L Bonello; F Paganelli; M Arpin-Bornet; P Auquier; J Sampol; F Dignat-George; P Barragan; L Camoin-Jau Journal: J Thromb Haemost Date: 2007-05-07 Impact factor: 5.824
Authors: J T Brandt; S L Close; S J Iturria; C D Payne; N A Farid; C S Ernest; D R Lachno; D Salazar; K J Winters Journal: J Thromb Haemost Date: 2007-09-26 Impact factor: 5.824
Authors: Amy Hai Yan Chan; Holly Foot; Christina Joanne Pearce; Rob Horne; Juliet Michelle Foster; Jeff Harrison Journal: PLoS One Date: 2022-03-21 Impact factor: 3.240
Authors: Valentina Forni Ogna; Isabelle Bassi; Isabelle Menetrey; Olivier Muller; Eric Tousset; Pierre Fontana; Eric Eeckhout; Chin B Eap; Bernard Vrijens; Michel Burnier; Grégoire Wuerzner Journal: Front Pharmacol Date: 2017-10-25 Impact factor: 5.810